New study tests best way to deliver antibiotics for sepsis
NCT ID NCT07398703
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at two methods of giving beta-lactam antibiotics to patients with sepsis or septic shock in the ICU: a slow 4-hour infusion versus a quick 30-minute infusion. Researchers will track survival at 90 days and whether the infection clears within 14 days. The goal is to find the most effective dosing strategy to improve outcomes for critically ill patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
beta-lactam antibiotics
What this could lead to
If successful, this could point toward a better way to give antibiotics to sepsis patients, potentially improving survival and recovery.
What could go wrong
This is a small, early-stage observational study with only 50 participants. Results may not apply to all sepsis patients, and the study hasn't started yet.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••